Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: A preclinical safety study in adult rats

Y. Ikeda, Y. Goto, Y. Yonemitsu, M. Miyazaki, T. Sakamoto, T. Ishibashi, T. Tabata, Y. Ueda, M. Hasegawa, S. Tobimatsu, K. Sueishi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Although lentivirus vectors hold promise for ocular gene therapy, they also have potential safety issues, particularly in the case of the current human immunodeficiency virus-based vectors. We recently developed a novel lentivirus vector derived from the nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm) to minimize these potentials. In this preclinical study, we evaluated whether SIV vector could be efficiently and safely applicable to retinal gene transfer by assessing the transgene expression, retinal function and histology over a 1-year period following subretinal injection in adult rats. The functional assessment via electroretinogram after both titers of SIV-lacZ (2.5 × 107 or 2.5 × 108 transducing units/ml) injection revealed both the dark and light adaptations to soon be impaired, in a dose-dependent manner, after a buffer injection as well, and all of them recovered to the control range by day 30. In both titers tested, the retinas demonstrated a frequent transgene expression mainly in the retinal pigment epithelium; however, the other retinal cells rarely expressed the transgene. Retinas exposed to a low titer virus showed no significant inflammatory reaction throughout the observation period, and also maintained the transgene expression over a 1-year period. In the retinas exposed to a high titer virus, however, mononuclear cell infiltration persisted in the subretinal area, and the retina that corresponded to the injected area finally underwent degeneration by around day 90. No retinal neoplastic lesions could be found in any animals over the 1-year period. We thus propose that SIV-mediated stable gene transfer might be useful for ocular gene transfer, however, more attention should be paid to avoiding complications when administering high titer lentivirus to the retina.

Original languageEnglish
Pages (from-to)1161-1169
Number of pages9
JournalGene Therapy
Volume10
Issue number14
DOIs
Publication statusPublished - Jul 1 2003

Fingerprint

Simian Immunodeficiency Virus
Lentivirus
Retina
Transgenes
Safety
Genes
Viral Load
Injections
Ocular Adaptation
Dark Adaptation
Cercopithecus aethiops
Retinal Pigment Epithelium
Genetic Therapy
Histology
Buffers
Observation
HIV

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer : A preclinical safety study in adult rats. / Ikeda, Y.; Goto, Y.; Yonemitsu, Y.; Miyazaki, M.; Sakamoto, T.; Ishibashi, T.; Tabata, T.; Ueda, Y.; Hasegawa, M.; Tobimatsu, S.; Sueishi, K.

In: Gene Therapy, Vol. 10, No. 14, 01.07.2003, p. 1161-1169.

Research output: Contribution to journalArticle

Ikeda, Y. ; Goto, Y. ; Yonemitsu, Y. ; Miyazaki, M. ; Sakamoto, T. ; Ishibashi, T. ; Tabata, T. ; Ueda, Y. ; Hasegawa, M. ; Tobimatsu, S. ; Sueishi, K. / Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer : A preclinical safety study in adult rats. In: Gene Therapy. 2003 ; Vol. 10, No. 14. pp. 1161-1169.
@article{cecd3ba5ee064467b121ffca5a7e6ed5,
title = "Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: A preclinical safety study in adult rats",
abstract = "Although lentivirus vectors hold promise for ocular gene therapy, they also have potential safety issues, particularly in the case of the current human immunodeficiency virus-based vectors. We recently developed a novel lentivirus vector derived from the nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm) to minimize these potentials. In this preclinical study, we evaluated whether SIV vector could be efficiently and safely applicable to retinal gene transfer by assessing the transgene expression, retinal function and histology over a 1-year period following subretinal injection in adult rats. The functional assessment via electroretinogram after both titers of SIV-lacZ (2.5 × 107 or 2.5 × 108 transducing units/ml) injection revealed both the dark and light adaptations to soon be impaired, in a dose-dependent manner, after a buffer injection as well, and all of them recovered to the control range by day 30. In both titers tested, the retinas demonstrated a frequent transgene expression mainly in the retinal pigment epithelium; however, the other retinal cells rarely expressed the transgene. Retinas exposed to a low titer virus showed no significant inflammatory reaction throughout the observation period, and also maintained the transgene expression over a 1-year period. In the retinas exposed to a high titer virus, however, mononuclear cell infiltration persisted in the subretinal area, and the retina that corresponded to the injected area finally underwent degeneration by around day 90. No retinal neoplastic lesions could be found in any animals over the 1-year period. We thus propose that SIV-mediated stable gene transfer might be useful for ocular gene transfer, however, more attention should be paid to avoiding complications when administering high titer lentivirus to the retina.",
author = "Y. Ikeda and Y. Goto and Y. Yonemitsu and M. Miyazaki and T. Sakamoto and T. Ishibashi and T. Tabata and Y. Ueda and M. Hasegawa and S. Tobimatsu and K. Sueishi",
year = "2003",
month = "7",
day = "1",
doi = "10.1038/sj.gt.3301973",
language = "English",
volume = "10",
pages = "1161--1169",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "14",

}

TY - JOUR

T1 - Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer

T2 - A preclinical safety study in adult rats

AU - Ikeda, Y.

AU - Goto, Y.

AU - Yonemitsu, Y.

AU - Miyazaki, M.

AU - Sakamoto, T.

AU - Ishibashi, T.

AU - Tabata, T.

AU - Ueda, Y.

AU - Hasegawa, M.

AU - Tobimatsu, S.

AU - Sueishi, K.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Although lentivirus vectors hold promise for ocular gene therapy, they also have potential safety issues, particularly in the case of the current human immunodeficiency virus-based vectors. We recently developed a novel lentivirus vector derived from the nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm) to minimize these potentials. In this preclinical study, we evaluated whether SIV vector could be efficiently and safely applicable to retinal gene transfer by assessing the transgene expression, retinal function and histology over a 1-year period following subretinal injection in adult rats. The functional assessment via electroretinogram after both titers of SIV-lacZ (2.5 × 107 or 2.5 × 108 transducing units/ml) injection revealed both the dark and light adaptations to soon be impaired, in a dose-dependent manner, after a buffer injection as well, and all of them recovered to the control range by day 30. In both titers tested, the retinas demonstrated a frequent transgene expression mainly in the retinal pigment epithelium; however, the other retinal cells rarely expressed the transgene. Retinas exposed to a low titer virus showed no significant inflammatory reaction throughout the observation period, and also maintained the transgene expression over a 1-year period. In the retinas exposed to a high titer virus, however, mononuclear cell infiltration persisted in the subretinal area, and the retina that corresponded to the injected area finally underwent degeneration by around day 90. No retinal neoplastic lesions could be found in any animals over the 1-year period. We thus propose that SIV-mediated stable gene transfer might be useful for ocular gene transfer, however, more attention should be paid to avoiding complications when administering high titer lentivirus to the retina.

AB - Although lentivirus vectors hold promise for ocular gene therapy, they also have potential safety issues, particularly in the case of the current human immunodeficiency virus-based vectors. We recently developed a novel lentivirus vector derived from the nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm) to minimize these potentials. In this preclinical study, we evaluated whether SIV vector could be efficiently and safely applicable to retinal gene transfer by assessing the transgene expression, retinal function and histology over a 1-year period following subretinal injection in adult rats. The functional assessment via electroretinogram after both titers of SIV-lacZ (2.5 × 107 or 2.5 × 108 transducing units/ml) injection revealed both the dark and light adaptations to soon be impaired, in a dose-dependent manner, after a buffer injection as well, and all of them recovered to the control range by day 30. In both titers tested, the retinas demonstrated a frequent transgene expression mainly in the retinal pigment epithelium; however, the other retinal cells rarely expressed the transgene. Retinas exposed to a low titer virus showed no significant inflammatory reaction throughout the observation period, and also maintained the transgene expression over a 1-year period. In the retinas exposed to a high titer virus, however, mononuclear cell infiltration persisted in the subretinal area, and the retina that corresponded to the injected area finally underwent degeneration by around day 90. No retinal neoplastic lesions could be found in any animals over the 1-year period. We thus propose that SIV-mediated stable gene transfer might be useful for ocular gene transfer, however, more attention should be paid to avoiding complications when administering high titer lentivirus to the retina.

UR - http://www.scopus.com/inward/record.url?scp=0042810885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042810885&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301973

DO - 10.1038/sj.gt.3301973

M3 - Article

C2 - 12833125

AN - SCOPUS:0042810885

VL - 10

SP - 1161

EP - 1169

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 14

ER -